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Charcot-Marie-Tooth disease type 2A (CMT2A) is an autosomal dominant axonal
form of peripheral neuropathy caused by mutations in the mitofusin 2 gene (MFN2),
which encodes a mitochondrial outer membrane protein that promotes
mitochondrial fusion. Emerging evidence also points to a role of MFN2 in the
regulation of mitochondrial metabolism. To examine whether mitochondrial
dysfunction is a feature of CMT2A, we used a transgenic mouse model expressing in
neurons a mutated R94Q form of human MFN2 shown to induce a CMT2A
phenotype. Oxygraphic and enzymatic measurements both revealed a combined
defect of mitochondrial complexes II and V (40 and 30% decrease, respectively) in
the brain of Tg-R94 mice, leading to a drastic decrease of ATP synthesis. These
deficiencies were reversed by the mitochondrial ATP-sensitive potassium channel
(mK(ATP)) inhibitor 5-hydroxydecanoate. Conversely, in controls and wild-type
human MFN2 mice, the mK(ATP) activator diazoxide mimicked the deficiency
observed with the R94Q mutation. The physical links between complexes II and V,
previously proposed as part of mK(ATP), were reinforced in Tg-R94Q mice. Our
results show that the R94Q MFN2 mutation induces a combined defect of complexes
II and V linked to the opening of mK(ATP), which could participate in the
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